Cure RTD Foundation

What it reported doing in 2025

Cure RTD Foundation is proud to have funded the five following research projects in advancement of the understanding and treatment of RTD:(a) $107,000 to Fondazione Bambino Gesu Ente Filantropico, a children's research hospital in Rome, Italy. The research project is titled "Unveiling the Underpinning of Mitochondrial Bioenergetics in RTD Motoneurons and Evaluation of Nerve Growth Factor Treatment as Therapeutic Treatment.(b) $52,000 to Children's Medical Research Institute in Australia. This is our second payment on a 2-year grant to begin understanding the eye defects of RTD patients by developing iPSC-derived Retinal Organoids: a 3D model to test the efficacy of the AAV Gene Therapy.(c) $50,000 to University of California, Irvine for a research project titled: "Post-translational modification (PTM) of hRFVT2 in human neuronal cells." The overall goal is to understand the molecular mechanisms regulating RF body homeostasis to design effective therapies for conditions like RTD. The working hypothesis is that hRFVT2 PTMs may be dysregulated in RTD pathologies, and the specific aim is to investigate the role and consequences of hRFVT2 post-translational modifications in the human fibroblast/neuronal system. The expected results will provide information on the neuronal RF transport process under normal conditions and how it is dysregulated in RTD, ultimately assisting in designing effective therapeutic strategies.(d) $14,350 to The Jackson Laboratory to fund a study titled "Pilot Biomarker Evaluation for Riboflavin Transport Deficiency (RTD)" with a purpose to validate histopathological and metabolomic/lipidomic as markers for RTD in B6.(e) $9,450 to UT Southwestern Medical Center for research on a SCL52A2 gene therapy project.

Financial Efficiency

• Mission deployment rate: 44.9%; rating input score 45
• Program expense ratio: 91.5%; rating input score 91
• Fundraising efficiency: $96.22 raised per $1 spent on fundraising; rating input score 84; 84th percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: 3 of 8 controls in place; rating input score 38
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Pass
  • Conducts field audits: Fail
  • May suspend future funding: Fail
  • Requires financial reports: Pass
  • Conducts site visits: Fail
  • Requires grant agreements: Fail
  • May require repayment: Fail
• Grant itemization coverage: 100%; rating input score 100; 78th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 80%; rating input score 80; 21st percentile among comparable filings
• Governance controls: 6 of 8 controls in place; rating input score 75
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: 54.4%; rating input score 92; 92nd percentile among comparable filings
• Total-asset coverage ratio: 6.41; rating input score 87; 87th percentile among comparable filings
• Liabilities to assets ratio: 0; rating input score 88; 88th percentile among comparable filings
• Officer compensation ratio: 5.9%; rating input score 48; 48th percentile among comparable filings

Growth

• Program expense growth: 23.4% per year; rating input score 100; 83rd percentile among comparable filings
• Revenue growth: 13% per year; rating input score 100; 70th percentile among comparable filings
• Asset growth: 27.4% per year; rating input score 100; 87th percentile among comparable filings